Basmisanil(RG1662，RG-1662)|cas 1159600-41-5

Basmisanil(RG1662，RG-1662)|cas 1159600-41-5

Basmisanil is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.

Product Name: Basmisanil(RG1662)|Cat No: DC9935|cas: 1159600-41-5 |Other Names: RG 1662; RG-1662; RG1662; RO5186582; RO-5186582; RO 5186582; Basmisanil

Basmisanil, also known as RG1662, RO5186582, is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome. As of August 2015, it is in phase II clinical trials for this indication. Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior.

For the research and scientific use only, not for human use!